Research I on Pharmacovigilance and Risk Control During Clinical Trials of New Drugs: The Enlightenment of the Requirements for Pharmacovigilance System in Europe and US to Chinese Sponsors

Zhi Huijing, Feng Hongyun, Zhou Lingyun, Yang Jianhong, Lü Xinhuan, Li Zelin, Li Hao

Chinese Pharmaceutical Affairs ›› 2022, Vol. 36 ›› Issue (6) : 616-623.

Chinese Pharmaceutical Affairs ›› 2022, Vol. 36 ›› Issue (6) : 616-623. DOI: 10.16153/j.1002-7777.2022.06.003

Research I on Pharmacovigilance and Risk Control During Clinical Trials of New Drugs: The Enlightenment of the Requirements for Pharmacovigilance System in Europe and US to Chinese Sponsors

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2022, 36(6): 616-623 https://doi.org/10.16153/j.1002-7777.2022.06.003

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}

Accesses

Citation

Detail
Sections
Recommended
京ICP备17052540号-4
Copyright © Chinese Pharmaceutical Affairs, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd.

/

〈 〉